8. Pharmacological Management Neurohormonal deactivation 1. A - - PowerPoint PPT Presentation

• 8. Pharmacological Management

Neurohormonal deactivation

• 1. Adrenaline
• Beta Blockers

Dose Side Effects Monitoring

Neurohormonal Deactivation

• 2. Angiotensin II
• ACE Inhibition

Dose Side Effects Monitoring

ARNI – Angiotensin receptor/Neprilysn Inhibition

ARNI

Neurohormonal Deactivation

• 3. Aldosterone
• MRA

Dose Side Effects Monitoring

Symptomatic management

• Diuretics

Loop/thiazide Dose Side Effects Monitoring

Other Pharmacological agents and contraindications

• Digoxin
• Oral Anticoagulations – NOACS
• Ivabradine
• Antianginals
• Antihypertensives
• Palliative Medications
• Contraindications

• 9. Non Pharmacological

Management

Non Pharmacological Management

• Anxiety/stress management
• Depression/low mood
• Support Groups
• Telehealth
• Salt intake
• Fluid intake
• Dry mouth

I would like to introduce………….!

• 11. Palliative Care

Heart failure has a poor prognosis

• Heart failure mortality remains unacceptably high.
• 30-40% of patients die within the first year of

diagnosis(Cowie et al, 2000; Hobbs et al, 2007).

• 1 year survival rates are worse than those for breast,

prostate and bladder cancer but better than those for lung and stomach cancer, and very similar to that for cancer of the colon (Stewart et al, 2000).

• Prognosis for valve disease and heart failure with

preserved ejection fraction is the same as that for patients with ejection fraction < 40% -LVSD.

• Deprivation associated with increased morbidity –

patients admit to hospital 5 years earlier than those living in more affluent areas.

• National Heart Failure Audit report from 2009/2010

– represents data relating to registered

• rganisations
• Mortality rate falls from 32% to 23 % for patients

who are followed up by a Cardiologist or have access to specialist heart failure services.

• Inpatient mortality 6.4% for cardiology ward

patients and 12.4% for general ward patients

• Heart failure patients more likely to die in hospital and

receive invasive investigations and treatment interventions that may go against their wishes (Lynn et al, 1997).

• Very few applications for financial support –DS1500 (Onac

et al, 2010).

• Absence of emotional support in the older heart failure

patient (Froggatt, 2001).

• Increased incidence of clinically significant depression –

associated with increases in mortality (Rutledge, 2006).

Inequalities

• Barriers to receiving information and choices in care

including Preferred Place of Care and Advanced Care Planning (Levenson et al, 2000; Boyd et al, 2004; NHS Improvement, 2010).

• Patients are living and dying with significant symptom

burden that is sometimes greater than patients dying from cancer (Anderson et al, 2001).

• Poor quality of life directly linked to symptom burden

(Bennett et al, 1998).

• Heart failure patients more likely to die in hospital and

receive invasive investigations and treatment interventions that may go against their wishes (Lynn et al, 1997).

• Very few applications for financial support –DS1500 (Onac

et al, 2010).

• Absence of emotional support in the older heart failure

patient (Froggatt, 2001).

• Increased incidence of clinically significant depression –

associated with increases in mortality (Rutledge, 2006).

Prognostication

• Advancing age
• Refractory symptoms despite optimal therapy
• 3 episodes of decompensation in less than 6 months
• Dependent with more than 3 ADL’s
• Cachexia (>5% non-fluid related weight loss)
• Progressive renal dysfunction
• Resistant hyponatraemia
• Serum albumin < 25g/l
• Multiple shocks “storms” from device

Jaarsma et al (2009)

Use your clinical acumen and experience

ESCAPE trial – large multicentre study indicated that nurses predictions of death were more accurate than a prognostic model based on BP, renal function, and exercise tolerance.

Yamokoski et al(2007)

Symptom Control

“Physical and psychosocial distress are directly related with heart failure pathophysiology therefore therapies that address the pathophysiology of heart failure and improve cardiac function similtaneously palliate heart failure related symptoms”

Goodlin (2009)

Patients with advanced heart failure often suffer with refractory symptoms including:

• Breathlessness
• Persistent cough
• Pain
• Fatigue
• Limitations in physical

activities

• Depression
• Anxiety
• Insomnia
• Cachexia
• Nausea
• Constipation

Symptom Control

• Oedema
• Dyspnoea
• Cough
• Pain
• Nausea & Vomiting
• Cachexia/anorexia
• Constipation
• Diuretics – synergistic blockade –IV-

Abx- Cream

• Diuretics – O2-Nitrates-NaCl nebs-low

dose morphine- Lorazepam

• Diuretics- ACE intolerant- Abx- NaCl

nebs- Codeine- low dose morphine

• Angina/hepatic – nitrates –

colchine/allopurinol – gout –MS – avoid NSAID – gel better option- paracetamol

• Avoid cyclizine -CKD 4 Haloperidol-

reduced peristalsis -Metoclopramide

• Refer to dietician – MUST score –

encourage small frequent meals of choice

• Routine aperients- Senna/Lactulose

Idrolax – Co-danthramer

Symptom Control

• Depression
• Anxiety
• Insomnia
• Fatigue and Lethargy
• Refer “Talking Therapies” –

Specialist Palliative Care - Avoid tricyclic –Choose SSRI- Citalopram, Sertraline, Mirtazepine if nausea and poor appetite

• Refer as above – Consider

Anxiolytic – Lorazepam, Diazepam, Fluoxetine, Citalopram

• Review of symptoms – sleep

hygiene- Consider -Temazepam- Lorazepam- Zopiclone

• Check Hb, U&E’s, TFT – refer for

aids and adaptations – OT- physion

Breaking down the barriers- current initiatives:

• British Heart Foundation commissioned National Council for

Palliative Care to research barriers to communication and “difficult” conversations from a patient/carer perspective

• Dying Matters –Lets talk about it – coalition of NCPC aims to

change public attitudes and behaviours around dying, death and bereavement.

• www.dyingmatters.org

BHF ICD deactivation at the end of life: Principles and practice A discussion document for healthcare professionals

• 10. Device Therapy

CRT and ICD

NYHA class QRS interval I II III IV <120 milliseconds ICD if there is a high risk of sudden cardiac death ICD and CRT not clinically indicated 120–149 milliseconds without LBBB ICD ICD ICD CRT-P 120–149 milliseconds with LBBB ICD CRT-D CRT-P or CRT-D CRT-P ≥150 milliseconds with

• r without LBBB

CRT-D CRT-D CRT-P or CRT-D CRT-P LBBB, left bundle branch block; NYHA, New York Heart Association

• https://www.youtube.com/watch?v=7hEw4o0

6Fwc

CRT